Associations of obesity phenotypes with weight change, cardiometabolic benefits, and type 2 diabetes incidence during a lifestyle intervention: results from the PREVIEW study.
Journal
International journal of obesity (2005)
ISSN: 1476-5497
Titre abrégé: Int J Obes (Lond)
Pays: England
ID NLM: 101256108
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
received:
13
01
2023
accepted:
01
06
2023
revised:
15
05
2023
medline:
21
8
2023
pubmed:
8
7
2023
entrez:
7
7
2023
Statut:
ppublish
Résumé
Some individuals with overweight/obesity may be relatively metabolically healthy (MHO) and have a lower risk of cardiovascular disease than those with metabolically unhealthy overweight/obesity (MUO). We aimed to compare changes in body weight and cardiometabolic risk factors and type 2 diabetes incidence during a lifestyle intervention between individuals with MHO vs MUO. This post-hoc analysis included 1012 participants with MHO and 1153 participants with MUO at baseline in the randomized trial PREVIEW. Participants underwent an eight-week low-energy diet phase followed by a 148-week lifestyle-based weight-maintenance intervention. Adjusted linear mixed models and Cox proportional hazards regression models were used. There were no statistically significant differences in weight loss (%) between participants with MHO vs MUO over 156 weeks. At the end of the study, weight loss was 2.7% (95% CI, 1.7%-3.6%) in participants with MHO and 3.0% (2.1%-4.0%) in those with MUO. After the low-energy diet phase, participants with MHO had smaller decreases in triglyceride (mean difference between MHO vs MUO 0.08 mmol·L Individuals with MUO had greater improvements in some cardiometabolic risk factors during the low-energy diet phase, but had smaller improvements during long-term lifestyle intervention than those with MHO.
Sections du résumé
BACKGROUND/OBJECTIVES
Some individuals with overweight/obesity may be relatively metabolically healthy (MHO) and have a lower risk of cardiovascular disease than those with metabolically unhealthy overweight/obesity (MUO). We aimed to compare changes in body weight and cardiometabolic risk factors and type 2 diabetes incidence during a lifestyle intervention between individuals with MHO vs MUO.
METHODS
This post-hoc analysis included 1012 participants with MHO and 1153 participants with MUO at baseline in the randomized trial PREVIEW. Participants underwent an eight-week low-energy diet phase followed by a 148-week lifestyle-based weight-maintenance intervention. Adjusted linear mixed models and Cox proportional hazards regression models were used.
RESULTS
There were no statistically significant differences in weight loss (%) between participants with MHO vs MUO over 156 weeks. At the end of the study, weight loss was 2.7% (95% CI, 1.7%-3.6%) in participants with MHO and 3.0% (2.1%-4.0%) in those with MUO. After the low-energy diet phase, participants with MHO had smaller decreases in triglyceride (mean difference between MHO vs MUO 0.08 mmol·L
CONCLUSIONS
Individuals with MUO had greater improvements in some cardiometabolic risk factors during the low-energy diet phase, but had smaller improvements during long-term lifestyle intervention than those with MHO.
Identifiants
pubmed: 37420008
doi: 10.1038/s41366-023-01328-y
pii: 10.1038/s41366-023-01328-y
doi:
Substances chimiques
Glucose
IY9XDZ35W2
Triglycerides
0
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
833-840Subventions
Organisme : Department of Health
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
Pays : United Kingdom
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Bluher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019;15:288–98.
doi: 10.1038/s41574-019-0176-8
pubmed: 30814686
Heymsfield SB, Wadden TA. Mechanisms, Pathophysiology, and Management of Obesity. N Engl J Med. 2017;376:254–66.
doi: 10.1056/NEJMra1514009
pubmed: 28099824
Eckel RH, Alberti KG, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2010;375:181–3.
doi: 10.1016/S0140-6736(09)61794-3
pubmed: 20109902
Tune JD, Goodwill AG, Sassoon DJ, Mather KJ. Cardiovascular consequences of metabolic syndrome. Transl Res. 2017;183:57–70.
doi: 10.1016/j.trsl.2017.01.001
pubmed: 28130064
pmcid: 5393930
Bluher M. Metabolically Healthy Obesity. Endocr Rev. 2020;41:405–20.
doi: 10.1210/endrev/bnaa004
Opio J, Croker E, Odongo GS, Attia J, Wynne K, McEvoy M. Metabolically healthy overweight/obesity are associated with increased risk of cardiovascular disease in adults, even in the absence of metabolic risk factors: A systematic review and meta-analysis of prospective cohort studies. Obes Rev. 2020;21:e13127.
doi: 10.1111/obr.13127
pubmed: 32869512
Zhou ZY, Macpherson J, Gray SR, Gill JMR, Welsh P, Celis-Morales C, et al. Are people with metabolically healthy obesity really healthy? A prospective cohort study of 381,363 UK Biobank participants. Diabetologia. 2021;64:1963–72.
doi: 10.1007/s00125-021-05484-6
pubmed: 34109441
pmcid: 8382657
Mongraw-Chaffin M, Foster MC, Anderson CAM, Burke GL, Haq N, Kalyani RR, et al. Metabolically Healthy Obesity, Transition to Metabolic Syndrome, and Cardiovascular Risk. J Am Coll Cardiol. 2018;71:1857–65.
doi: 10.1016/j.jacc.2018.02.055
pubmed: 29699611
pmcid: 6002856
Lin H, Zhang L, Zheng R, Zheng Y. The prevalence, metabolic risk and effects of lifestyle intervention for metabolically healthy obesity: a systematic review and meta-analysis: A PRISMA-compliant article. Medicine (Baltimore). 2017;96:e8838.
doi: 10.1097/MD.0000000000008838
pubmed: 29381992
Eckel N, Li Y, Kuxhaus O, Stefan N, Hu FB, Schulze MB. Transition from metabolic healthy to unhealthy phenotypes and association with cardiovascular disease risk across BMI categories in 90 257 women (the Nurses’ Health Study): 30 year follow-up from a prospective cohort study. Lancet Diabetes Endocrinol. 2018;6:714–24.
doi: 10.1016/S2213-8587(18)30137-2
pubmed: 29859908
Diabetes Prevention Program Outcomes Study Research G, Orchard TJ, Temprosa M, Barrett-Connor E, Fowler SE, Goldberg RB, et al. Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study. Diabet Med. 2013;30:46–55.
doi: 10.1111/j.1464-5491.2012.03750.x
Salas-Salvado J, Diaz-Lopez A, Ruiz-Canela M, Basora J, Fito M, Corella D, et al. Effect of a Lifestyle Intervention Program With Energy-Restricted Mediterranean Diet and Exercise on Weight Loss and Cardiovascular Risk Factors: One-Year Results of the PREDIMED-Plus Trial. Diabetes Care. 2019;42:777–88.
doi: 10.2337/dc18-0836
pubmed: 30389673
Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369:145–54.
doi: 10.1056/NEJMoa1212914
pubmed: 23796131
Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. The Lancet. 2009;374:1677–86.
doi: 10.1016/S0140-6736(09)61457-4
Lindstrom J, Peltonen M, Eriksson JG, Ilanne-Parikka P, Aunola S, Keinanen-Kiukaanniemi S, et al. Improved lifestyle and decreased diabetes risk over 13 years: long-term follow-up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia. 2013;56:284–93.
doi: 10.1007/s00125-012-2752-5
pubmed: 23093136
Raben A, Vestentoft PS, Brand‐Miller J, Jalo E, Drummen M, Simpson L, et al. PREVIEW‐Results from a 3‐year randomised 2 x 2 factorial multinational trial investigating the role of protein, glycemic index and physical activity for prevention of type‐2 diabetes. Diabetes Obes Metab. 2020;23:324–37.
doi: 10.1111/dom.14219
pubmed: 33026154
pmcid: 8120810
Zhu R, Craciun I, Bernhards-Werge J, Jalo E, Poppitt SD, Silvestre MP, et al. Age-and sex-specific effects of a long-term lifestyle intervention on body weight and cardiometabolic health markers in adults with prediabetes: results from the diabetes prevention study PREVIEW. Diabetologia. 2022;65:1262–77.
doi: 10.1007/s00125-022-05716-3
pubmed: 35610522
pmcid: 9283166
Zhu R, Jalo E, Silvestre MP, Poppitt SD, Handjieva-Darlenska T, Handjiev S, et al. Does the Effect of a 3-Year Lifestyle Intervention on Body Weight and Cardiometabolic Health Differ by Prediabetes Metabolic Phenotype? A Post Hoc Analysis of the PREVIEW Study. Diabetes Care. 2022;45:2698–708.
doi: 10.2337/dc22-0549
pubmed: 35696263
Fogelholm M, Larsen TM, Westerterp-Plantenga M, Macdonald I, Martinez JA, Boyadjieva N, et al. PREVIEW: prevention of diabetes through lifestyle intervention and population studies in Europe and around the world. design, methods, and baseline participant description of an adult cohort enrolled into a three-year randomised clinical trial. Nutrients. 2017;9:632.
doi: 10.3390/nu9060632
pubmed: 28632180
pmcid: 5490611
American Diabetes Association Professional Practice Committee. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2022. Diabetes Care. 2022;45(Suppl 1):S17–S38.
doi: 10.2337/dc22-S002
Christensen P, Meinert Larsen T, Westerterp-Plantenga M, Macdonald I, Martinez JA, Handjiev S, et al. Men and women respond differently to rapid weight loss: Metabolic outcomes of a multi-centre intervention study after a low-energy diet in 2500 overweight, individuals with pre-diabetes (PREVIEW). Diabetes Obes Metab. 2018;20:2840–51.
doi: 10.1111/dom.13466
pubmed: 30088336
pmcid: 6282840
Sanchez-Inigo L, Navarro-Gonzalez D, Fernandez-Montero A, Pastrana-Delgado J, Martinez JA. The TyG index may predict the development of cardiovascular events. Eur J Clin Invest. 2016;46:189–97.
doi: 10.1111/eci.12583
pubmed: 26683265
World Health Organization. Global Recommendations on Physical Activity for Health. https://www.who.int/dietphysicalactivity/global-PA-recs-2010.pdf . Assessed on Jan, 2021.
Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–97.
Alberti KGM, Zimmet P, Shaw J. The metabolic syndrome—a new worldwide definition. The Lancet. 2005;366:1059–62.
doi: 10.1016/S0140-6736(05)67402-8
Karelis AD, Messier V, Brochu M, Rabasa-Lhoret R. Metabolically healthy but obese women: effect of an energy-restricted diet. Diabetologia. 2008;51:1752–4.
doi: 10.1007/s00125-008-1038-4
pubmed: 18504546
Shin MJ, Hyun YJ, Kim OY, Kim JY, Jang Y, Lee JH. Weight loss effect on inflammation and LDL oxidation in metabolically healthy but obese (MHO) individuals: low inflammation and LDL oxidation in MHO women. Int J Obes (Lond). 2006;30:1529–34.
doi: 10.1038/sj.ijo.0803304
pubmed: 16552406
Ruiz JR, Ortega FB, Labayen I. A weight loss diet intervention has a similar beneficial effect on both metabolically abnormal obese and metabolically healthy but obese premenopausal women. Ann Nutr Metab. 2013;62:223–30.
doi: 10.1159/000345026
pubmed: 23571719
Kantartzis K, Machann J, Schick F, Rittig K, Machicao F, Fritsche A, et al. Effects of a lifestyle intervention in metabolically benign and malign obesity. Diabetologia. 2011;54:864–8.
doi: 10.1007/s00125-010-2006-3
pubmed: 21174075
Janiszewski PM, Ross R. Effects of weight loss among metabolically healthy obese men and women. Diabetes Care. 2010;33:1957–9.
doi: 10.2337/dc10-0547
pubmed: 20573755
pmcid: 2928342
Gardner CD, Offringa LC, Hartle JC, Kapphahn K, Cherin R. Weight loss on low-fat vs. low-carbohydrate diets by insulin resistance status among overweight adults and adults with obesity: A randomized pilot trial. Obesity. 2016;24:79–86.
doi: 10.1002/oby.21331
pubmed: 26638192
Dalzill C, Nigam A, Juneau M, Guilbeault V, Latour E, Mauriege P, et al. Intensive lifestyle intervention improves cardiometabolic and exercise parameters in metabolically healthy obese and metabolically unhealthy obese individuals. Can J Cardiol. 2014;30:434–40.
doi: 10.1016/j.cjca.2013.11.033
pubmed: 24561010
Hinnouho G-M, Czernichow S, Dugravot A, Nabi H, Brunner EJ, Kivimaki M, et al. Metabolically healthy obesity and the risk of cardiovascular disease and type 2 diabetes: the Whitehall II cohort study. Eur Heart J. 2015;36:551–9.
doi: 10.1093/eurheartj/ehu123
pubmed: 24670711
Stefan N, Haring HU, Schulze MB. Metabolically healthy obesity: the low-hanging fruit in obesity treatment? Lancet Diabetes Endocrinol. 2018;6:249–58.
doi: 10.1016/S2213-8587(17)30292-9
pubmed: 28919065
Sharma AM, Kushner RF. A proposed clinical staging system for obesity. Int J Obes (Lond). 2009;33:289–95.
doi: 10.1038/ijo.2009.2
pubmed: 19188927
Tsatsoulis A, Paschou SA. Metabolically Healthy Obesity: Criteria, Epidemiology, Controversies, and Consequences. Curr Obes Rep. 2020;9:109–20.
doi: 10.1007/s13679-020-00375-0
pubmed: 32301039
van Vliet-Ostaptchouk JV, Nuotio M-L, Slagter SN, Doiron D, Fischer K, Foco L, et al. The prevalence of metabolicsyndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies. BMC Endocr Disord. 2014;14:9.
doi: 10.1186/1472-6823-14-9
pubmed: 24484869
pmcid: 3923238